



**Supplementary Fig. 3.** Cumulative incidence and number at risk of (A) total stroke, (B) ischemic stroke, and (C) hemorrhagic stroke in sodium-glucose cotransporter-2 inhibitor (SGLT-2i)-treated and thiazolidinedione (TZD)-treated groups (sensitivity analysis: including the patients prescribed study drugs at least once).